Your browser doesn't support javascript.
loading
Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape.
Al-Khabori, Murtadha K; Alhuraiji, Ahmad; Alam, Arif R; Khan, Faraz A; El Omri, Halima; Osman, Hani Y; AaL Yaseen, Hasan M; Al Bulushi, Mahdiya Pir; Pandita, Ramesh K; Marashi, Mahmoud M.
Affiliation
  • Al-Khabori MK; Hematology and Bone Marrow Transplantation Department, Sultan Qaboos University, Muscat, Oman.
  • Alhuraiji A; Department of Hematology, Kuwait Cancer Control Center, Kuwait, Kuwait.
  • Alam AR; Department of Oncology, Tawam Hospital, Al Ain, UAE.
  • Khan FA; American Hospital Dubai, Dubai, UAE.
  • El Omri H; Department of Hematology and Bone Marrow Transplant NCCCR-Hamad Medical Corporation, Doha, Qatar.
  • Osman HY; Department of Oncology, Tawam Hospital, Al Ain, UAE.
  • AaL Yaseen HM; Dubai Hospital, Dubai, UAE.
  • Al Bulushi MP; Royal Hospital, Muscat, Oman.
  • Pandita RK; Department of Hematology, Kuwait Cancer Control Center, Kuwait, Kuwait.
  • Marashi MM; Mediclinic City Hospital and Dubai Hospital, Dubai, UAE.
JCO Glob Oncol ; 10: e2300165, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38843471
ABSTRACT

PURPOSE:

AML is a heterogeneous hematologic malignancy. Region-specific recommendations for AML management can enhance patient outcomes. This article aimed to develop recommendations for the Gulf Cooperation Council (GCC) countries.

METHODS:

Ten AML panel members from Kuwait, Oman, Qatar, and the United Arab Emirates (KOQU) participated in a modified two-round Delphi process. The panel first identified the unmet regional needs and finalized a list of core variables. Next, they voted on iterative statements drawn from international recommendations and provided feedback via a questionnaire. Consensus voting ≤70% was discussed, and additional clinical decision making statements were suggested. At round closure, a consensus vote took place on revised statements.

RESULTS:

The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent genetic abnormalities was required for a diagnosis of AML. Key consensus was reached for different treatment stages. The panel noted that older patients pose a challenge because of poor cytogenetics and genetic anomalies and require different treatment approaches. The panel recommended venetoclax-hypomethylating agents; fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor; and targeted therapy for AML relapsed/refractory disease. Supportive care is considered on the basis of prevailing organisms and drug resistance.

CONCLUSION:

The GCC KOQU's consensus-based recommendations for managing AML include an evidence-based and region-specific framework.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Consensus Limits: Humans Country/Region as subject: Asia Language: En Journal: JCO Glob Oncol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Consensus Limits: Humans Country/Region as subject: Asia Language: En Journal: JCO Glob Oncol Year: 2024 Document type: Article Affiliation country: